Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 498

1.

A multicolour fluorescence in situ hybridization test predicts recurrence in patients with high-risk superficial bladder tumours undergoing intravesical therapy.

Whitson J, Berry A, Carroll P, Konety B.

BJU Int. 2009 Aug;104(3):336-9. doi: 10.1111/j.1464-410X.2009.08375.x. Epub 2009 Feb 10.

2.

Conservative treatment of high grade superficial bladder tumours.

Trinchieri A, Bonacina P, Butti A, Cappoli S, Esposito N, Invernizzi S, Librizzi A, Locatelli G.

Arch Ital Urol Androl. 2005 Dec;77(4):215-8.

PMID:
16444936
3.

The prognostic value of cytology and fluorescence in situ hybridization in the follow-up of nonmuscle-invasive bladder cancer after intravesical Bacillus Calmette-Guérin therapy.

Savic S, Zlobec I, Thalmann GN, Engeler D, Schmauss M, Lehmann K, Mattarelli G, Eichenberger T, Dalquen P, Spieler P, Schoenegg R, Gasser TC, Sulser T, Forster T, Zellweger T, Casella R, Bubendorf L.

Int J Cancer. 2009 Jun 15;124(12):2899-904. doi: 10.1002/ijc.24258.

4.

Superficial bladder tumours: analysis of prognostic factors and construction of a predictive index.

Ali-El-Dein B, Sarhan O, Hinev A, Ibrahiem el-HI, Nabeeh A, Ghoneim MA.

BJU Int. 2003 Sep;92(4):393-9.

5.

The effect of gender on response to bacillus Calmette-Guérin therapy for patients with non-muscle-invasive urothelial carcinoma of the bladder.

Boorjian SA, Zhu F, Herr HW.

BJU Int. 2010 Aug;106(3):357-61. doi: 10.1111/j.1464-410X.2009.09137.x. Epub 2009 Dec 11.

6.

Monitoring intravesical therapy for superficial bladder cancer using fluorescence in situ hybridization.

Kipp BR, Karnes RJ, Brankley SM, Harwood AR, Pankratz VS, Sebo TJ, Blute MM, Lieber MM, Zincke H, Halling KC.

J Urol. 2005 Feb;173(2):401-4.

PMID:
15643180
7.
9.

The optimum timing of radical cystectomy for patients with recurrent high-risk superficial bladder tumour.

Solsona E, Iborra I, Rubio J, Casanova J, Almenar S.

BJU Int. 2004 Dec;94(9):1258-62.

10.

Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guérin with a reduced dose of 27 mg in superficial bladder cancer.

Martínez-Piñeiro JA, Flores N, Isorna S, Solsona E, Sebastián JL, Pertusa C, Rioja LA, Martínez-Piñeiro L, Vela R, Camacho JE, Nogueira JL, Pereira I, Resel L, Muntañola P, Galvis F, Chesa N, De Torres JA, Carballido J, Bernuy C, Arribas S, Madero R; for CUETO (Club Urológico Español de Tratamiento Oncológico).

BJU Int. 2002 May;89(7):671-80.

11.

Clinical utility of fluorescent in situ hybridization for the surveillance of bladder cancer patients treated with bacillus Calmette-Guérin therapy.

Mengual L, Marín-Aguilera M, Ribal MJ, Burset M, Villavicencio H, Oliver A, Alcaraz A.

Eur Urol. 2007 Sep;52(3):752-9. Epub 2007 Mar 12.

PMID:
17379395
12.

Prognostic factors in patients with carcinoma in situ treated with intravesical bacille Calmette-Guérin.

Andius P, Damm O, Holmäng S.

Scand J Urol Nephrol. 2004;38(4):285-90.

PMID:
15669587
13.

[Results of adjuvant intravesical Bacillus Calmette-Guérin therapy for grade 3 superficial bladder cancer].

Yumura Y, Oogo Y, Takase K, Hamano A, Yamashita Y, Noguchi S, Satomi Y.

Hinyokika Kiyo. 2004 Nov;50(11):767-71. Japanese.

PMID:
15628536
14.

Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin.

Thalmann GN, Sermier A, Rentsch C, Möhrle K, Cecchini MG, Studer UE.

J Urol. 2000 Dec;164(6):2129-33.

PMID:
11061941
15.
16.

UroVysion testing can lead to early identification of intravesical therapy failure in patients with high risk non-muscle invasive bladder cancer.

Whitson JM, Berry AB, Carroll PR, Konety BR.

Int Braz J Urol. 2009 Nov-Dec;35(6):664-70; discussion 671-2.

17.

The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer.

Solsona E, Iborra I, Dumont R, Rubio-Briones J, Casanova J, Almenar S.

J Urol. 2000 Sep;164(3 Pt 1):685-9.

PMID:
10953125
18.
19.
20.

Surveillance of patients with bladder carcinoma using fluorescent in-situ hybridization on bladder washings.

Bergman J, Reznichek RC, Rajfer J.

BJU Int. 2008 Jan;101(1):26-9. Epub 2007 Sep 10.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk